Merck KGaA, of Darmstadt, Germany, said its EMD Serono subsidiary inked a research agreement with Pfizer Inc., of New York, and the Broad Institute in Cambridge, Mass., which will focus on the genomic profiling of systemic lupus erythematosus and lupus nephritis patients.